Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.30 |
| ▸ | MGLL | Q99685 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719301 | 1.00 | TBXAS1 (0.35) | TBXAS1RORCCNR1CNR2CYP17A1 | |
| SCHEMBL23431986 | 1.00 | TBXAS1 (0.35) | TBXAS1RORCCNR1CNR2CYP17A1 | |
| SCHEMBL22807585 | 0.98 | RORC (0.36) | TBXAS1RORCCNR1CNR2 | |
| SCHEMBL24936176 | 0.77 | TBXAS1 (0.37) | TBXAS1CNR1CNR2 | |
| SCHEMBL21573048 | 0.77 | RORC (0.37) | RORCCYP17A1CYP3A4 | |
| SCHEMBL24689847 | 0.75 | CCNB2 (0.32) | — | |
| SCHEMBL21719306 | 0.72 | GGPS1 (0.30) | — | |
| SCHEMBL21718557 | 0.72 | ALDH1A1 (0.34) | CNR1CNR2CYP3A4 | |
| SCHEMBL22236494 | 0.71 | NPC1 (0.35) | CNR1CNR2 | |
| SCHEMBL21719216 | 0.71 | NPC1 (0.35) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | Chiromics, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-10870625-B2 | Zwitterionic propargyl-linked antifolates useful for treating bacterial infections | UNIVERSITY OF CONNECTICUT (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | Chiromics, LLC (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | OPRM1, OPRK1, OPRD1 | TBXAS1 1443/4885RORC 452/4885CNR1 7/4885 |
| US-10870625-B2 | Zwitterionic propargyl-linked antifolates useful for treating bacterial infections | DHFR, FOLR1, FOLR2 | TBXAS1 2355/4885RORC 2434/4885CNR1 1932/4885 |
| US-20230075221-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVE AND PREPARATION METHOD, HERBICIDAL COMPOSITION AND APPLICATION THEREOF | TH, CYP4X1, CYP4B1 | TBXAS1 2115/4885RORC 1814/4885CNR1 1357/4885 |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | TBXAS1 1081/4885RORC 2270/4885CNR1 1093/4885 |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | OPRM1, OPRK1, OPRD1 | TBXAS1 1443/4885RORC 452/4885CNR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.